Charles Dunn, MD
MOHS-Micrographic Surgery · Port Orange, FLNPI 1477976082
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (52.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sanofi accounts for 66.5% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2023 at $6,066 and has fallen 87.0% since, to $789 in 2025.
Across 120 payments — averaging $71.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- AbbVie$734
- Pfizer$398
- Regeneron Healthcare Solutions, Inc.$381
- LEO Pharma Inc.$284
- Amgen$264
- plus $814 from 13 others
What the payments were for
- Consulting fees$4,53653%
- Travel & lodging$7759%
- Food & beverage$3,27738%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 13 | $5,713 |
| AbbVie | 36 | $734 |
| Pfizer | 9 | $398 |
| Regeneron Healthcare Solutions, Inc. | 16 | $381 |
| LEO Pharma Inc. | 8 | $284 |
| Amgen | 8 | $264 |
| Novartis | 5 | $201 |
| Johnson & Johnson | 7 | $122 |
| Dermavant Sciences, Inc. | 1 | $97 |
| E.r. Squibb & Sons, L.L.C. | 4 | $77 |
| Sun Pharmaceutical Industries Inc. | 1 | $63 |
| Incyte Corporation | 3 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $53 |
| Galderma Laboratories, L.p. | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| Biofrontera Inc. | 1 | $22 |
| Almirall LLC | 1 | $20 |
| UCB, Inc. | 1 | $18 |
| Mayne Pharma Commercial LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,589 in reported general payments places this provider in the 80th percentile of 141 mohs-micrographic surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 81 | $5,339 |
| Ketoconazole | 75 | $1,788 |
| Clobetasol Propionate | 50 | $1,719 |
| Triamcinolone Acetonide | 90 | $1,654 |
| Doxycycline Hyclate | 108 | $927 |
| Desonide | 12 | $493 |
| Mupirocin | 39 | $268 |
| Clindamycin Phosphate | 13 | $250 |
| Minoxidil | 26 | $212 |
| Cephalexin | 20 | $162 |
| Hydrocortisone | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Port Orange
- Andrew WeinsteinBoynton Beach$197K
- Armand CognettaTallahassee$139K
- Scott FoskoGainesville$100K
- Paul BenedettoCoral Springs$96K
- Jeremy SunseriPanama City$81K
- Shawna FlanaganJupiter$74K
- Martin ZaiacMiami Beach$61K
- Jason RizzoEstero$60K
- Andrew JaffePalm Beach Gardens$52K
- Kenneth WallaceOcala$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.